Advair Diskus
Advair Diskus Official FDA information, side effects and uses.
Posted by Advair Diskus (Advair-Diskus) on Thu, 30 Aug 2007 00:16:31 +0000
TRENTON, N.J. (AP) — Under growing scrutiny since the blockbuster painkiller Vioxx was pulled from the market, the Food and Drug Administration in recent months has rejected a slew of experimental drugs or delayed their approval and required more data.
GSK receives FDA 'not approvable letter' for Advair for COPD (News-Medical-Net)
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the supplemental drug application for the 500/50 strength of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the treatment of patients with chronic obstructive pulmonary disease (COPD).
GSK Receives Decision From FDA On Advair 500/50 For COPD (Medical News Today)
GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the supplemental drug application for the 500/50 strength of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the treatment of patients with chronic obstructive pulmonary disease (COPD). [click link for full article]
Glaxo's Advair Diskus Inhaler Fails to Win Wider Use in U.S. (Bloomberg.com)
Aug. 8 (Bloomberg) -- GlaxoSmithKline Plc failed to win U.S. approval to market the strongest dose of the asthma inhaler Advair Diskus, the company's top-selling product, as a treatment for symptoms of a common lung disease often linked to smoking.
FDA's caution about new drugs may hurt firms (Fort Worth Star-Telegram)
By LINDA A. JOHNSON Under growing scrutiny since the blockbuster painkiller Vioxx was pulled from the market in 2004, the Food and Drug Administration in recent months has rejected a slew of experimental drugs or delayed their approval and required more data. The impact Besides keeping off the market drugs that some patients might desperately need, the rejections have battered drug company ...
